OBJECTIVE: We hypothesized that body composition would be similar among neonates of women with gestational diabetes (GDM) treated withglyburide or insulin. STUDY DESIGN:Women with GDM requiring medical therapy were randomized to insulin or glyburide. The primary outcome was percent neonatal fat mass measured by total body electrical conductivity. Secondary outcomes included anthropometrics, glycemic control, and biomarkers. Statistical analysis included Student t test, chi(2), and regression modeling. RESULTS: Eighty-two neonates underwent postnatal measurements. Baseline factors were not different by group. Neonatal percent fat mass did not differ between treatment groups (11.2 +/- 4.2 vs 12.8 +/- 5.7). Fat mass, body mass index, ponderal index, skinfold sum, and arm fat area were not different when analyzed by intent to treat or actual treatment group. Cord concentrations of biomarkers were also similar. CONCLUSION: There was no difference in neonatal adiposity in infants of women treated for GDM with glyburide or insulin.
RCT Entities:
OBJECTIVE: We hypothesized that body composition would be similar among neonates of women with gestational diabetes (GDM) treated with glyburide or insulin. STUDY DESIGN:Women with GDM requiring medical therapy were randomized to insulin or glyburide. The primary outcome was percent neonatal fat mass measured by total body electrical conductivity. Secondary outcomes included anthropometrics, glycemic control, and biomarkers. Statistical analysis included Student t test, chi(2), and regression modeling. RESULTS: Eighty-two neonates underwent postnatal measurements. Baseline factors were not different by group. Neonatal percent fat mass did not differ between treatment groups (11.2 +/- 4.2 vs 12.8 +/- 5.7). Fat mass, body mass index, ponderal index, skinfold sum, and arm fat area were not different when analyzed by intent to treat or actual treatment group. Cord concentrations of biomarkers were also similar. CONCLUSION: There was no difference in neonatal adiposity in infants of women treated for GDM with glyburide or insulin.
Authors: April M Teague; David A Fields; Christopher E Aston; Kevin R Short; Timothy J Lyons; Steven D Chernausek Journal: Reprod Biol Endocrinol Date: 2015-06-26 Impact factor: 5.211